Le Lézard
Classified in: Health
Subjects: PET, ANW

Bactana Inks Distribution Agreement With France-Based ArcaNatura


FARMINGTON, Conn., Jan. 26, 2022 /PRNewswire-PRWeb/ -- Bactana Corp, a company isolating novel postbiotics to treat diabetes and other diseases while also developing products to reduce the use of antibiotics in livestock production, today announced that they have signed a distribution agreement with France-based ArcaNatura SAS to launch Bactana's first commercial product, PawsniTM Glucose Control.

ArcaNatura is one of the largest providers of pet supplements to French veterinary clinics and is the exclusive distributor for several of the country's best selling brands, including Dasuquin®, Cosequin®, and Denamarin®.

"Pawsni Glucose Control is one of the most innovative new pet products I have seen in years," said Serge Martinod, DVM, PhD., ArcaNatura's CSO. "We are excited to support Bactana's first European product launch."

FPZ-100, Bactana's patent pending active ingredient in Pawsni Glucose Control, has been shown to significantly reduce diabetic and prediabetic blood markers in multiple placebo-controlled mouse trials without causing undesirable hypoglycemic side effects. Bactana is developing a complete line of Pawsni branded products that all utilize the scientifically tested benefits of FPZ-100 to improve the lives of companion animals.

"ArcaNatura's years of experience developing and selling innovative natural solutions that support complex pet ailments makes them the ideal partner for Bactana as we prepare to launch our first product throughout the world" said John Kallassy, Bactana's CEO.

About Bactana:
Bactana is a global development stage company at the forefront of identifying and isolating therapeutically significant molecules expressed from commensal anaerobic microbes to deliver safe and effective therapies for pets and to provide sustainable solutions for livestock. For more information, please contact [email protected].

About ArcaNatura:
Created by French veterinary surgeons, ArcaNatura SAS offers new methods of managing companion animal pathologies by utilizing a multimodal approach that includes reinforcement of disease prevention. ArcaNatura focuses on reducing or eliminating adverse side effects by providing natural products that decrease the reliance of synthetic drugs. Their mission is to increase the quality of life of animals and provide convenience and satisfaction to those who care for them.

https://www.arcanatura.fr/

Media Contact

John Kallassy, Bactana, 203-716-1230, [email protected]

 

SOURCE Bactana


These press releases may also interest you

13 aoû 2022
At least 5% of Americans suffer from chronic low back pain. [1] Over $630 billion is spent annually on costs to society [2], and chiropractic care is essential in managed post-surgical spinal pain [3] and scoliosis [4]. To prepare clinicians...

13 aoû 2022
Ziegler is pleased to announce the successful closing of Shenandoah Valley Westminster-Canterbury's $71,000,000 Series 2022A and 2022B Bonds for the Senior Living Finance Practice. Shenandoah Valley Westminster-Canterbury (SVWC) is a Virginia...

12 aoû 2022
The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of LifeStance Health Group, Inc. common stock issued in connection with LifeStance Health's June 10, 2021 initial...

12 aoû 2022
An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate (ADC) technology and...

12 aoû 2022
Core One Labs Inc. , , (the "Company" or "Core One") is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. ("Awakened") have successfully produced a precursor that can be...

12 aoû 2022
Following the passage of the Inflation Reduction Act, Peter L. Saltonstall, President and CEO, the National Organization for Rare Disorders (NORD), issued the following statement:...



News published on 26 january 2022 at 09:00 and distributed by: